Acquisition signals shift from US market
Article Abstract:
The US biotech market is losing its former center-stage position for European companies judging by the $1.6 billion cash acquisition of Transkaryotic Therapies. An increasingly difficult business and regulatory environment in the US explains that a move may inspire other biopharmaceutical companies and it is believed that the acquisition is addressing a strategic need to build up Shire's non-US operations at the expense of its US effort.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
UK urged to plug "bioprocessing gap"
Article Abstract:
A working group known as the Bioscience Innovation and Growth Team (BIGT-London) recommends the creation of bioprocess training modules, aimed at regional training of operators and technicians plus national training modules for bioprocessing leaders. This will help to improve the biomanufacturing skill workforce that is very much required in UK.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: An investigation of transactions data for NYSE (New York Stock Exchange) stocks. Volatility increases subsequent to NYSE and AMEX stock splits
- Abstracts: Lula's scorecard shows promise. Lula struggles to balance promises with stability
- Abstracts: Temporary regulations issued for mergers involving disregarded entities. Exercise of option to invest in a partnership was a disguised sale
- Abstracts: McIntosh to answer questions. Limits placed on UK 'super casinos'. Germany: a new horizon?
- Abstracts: India's strategy to bridge the public-private divide. Kiran Mazumdar-Shaw. Indian biogenerics industry emerges